Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs.
| Autor: | Karpf DM; Biopharmaceutical Research Unit, Novo Nordisk A/S, Måløv, Denmark., Kjalke M, Thim L, Agersø H, Merricks EP, Defriess N, Nichols TC, Ezban M |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2011 Sep; Vol. 17 (5), pp. e963-8. Date of Electronic Publication: 2011 Jun 20. |
| DOI: | 10.1111/j.1365-2516.2011.02580.x |
| Abstrakt: | N8, a new recombinant factor VIII (rFVIII) compound developed for the treatment of haemophilia A, is produced in Chinese hamster ovary (CHO) cells and formulated without human- or animal-derived materials. The aim of the present study was to compare the pharmacokinetics (PK) and the procoagulant effect, measured by ex vivo whole blood clot formation, of N8 and a commercial rFVIII in a cross-over study in haemophilia A dogs. N8 and Advate® (100 IU kg⁻¹) were administered intravenously to three haemophilia A dogs. Blood was sampled between 0 and 120 h postdose and FVIII:C analysed. PK parameters maximum plasma concentration, area under the curve, half-life (t(½)), clearance, mean residence time (MRT) and volume of distribution and incremental recovery were calculated. Whole blood clotting time (WBCT) and thromboelastography (TEG®) were used to determine the haemostatic potential. No adverse reactions were observed with N8 or Advate ®. N8 and Advate® exhibited similar PK parameters, with t(½) 7.7-11 h and MRT 11-14 h. Both rFVIII compounds corrected the prolonged WBCT (> 48 min) to the range of normal dogs (8-12 min), i.e. N8 to 7.5-10.5 min and Advate® to 7.5-11.5 min. N8 and Advate® also normalized the whole blood clot formation according to TEG®. The native whole blood clotting assays (WBCT, TEG®) appeared to be more sensitive to low concentrations of FVIII than assays in citrated plasma samples. In conclusion, comparison of N8 and Advate ® in haemophilia A dogs revealed similar safety, similar PK and similar effects in whole blood clot formation assays. (© 2011 Blackwell Publishing Ltd.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|